Interaction of hemostatic genetics with hormone therapy: New insights to explain arterial thrombosis in postmenopausal women

Chest

Volumn 121, Issue 3, 2002, Pages 906-920

  Braunstein, Joel B ^a   Kershner, Dawn Warner ^a   Bray, Paul ^a   Gerstenblith, Gary ^a   Schulman, Steven P ^a   Post, Wendy S ^a   Blumenthal, Roger S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Arterial thrombosis; Estrogen therapy; Genetic polymorphisms; Hemostatic factors

Indexed keywords

BLOOD CLOTTING FACTOR 7; CONJUGATED ESTROGEN; FIBRINOGEN; MEDROXYPROGESTERONE ACETATE; PROTHROMBIN;

ARTERY COMPLIANCE; ARTERY THROMBOSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; FIBRINOLYSIS; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HORMONAL THERAPY; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOCYTE; THROMBOSIS;

EID: 0036202887     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.121.3.906     Document Type: Review

References (136)

1. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
2. Fibrinogen and factor VII in the prediction of coronary risk: Results from the PROCAM study in healthy men
3. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
4. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men
5. Ischemic heart disease and platelet aggregation: The Caerphilly collaborative heart disease study
6. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease
7. Enhancement by factor V leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing third-generation progestagen
8. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V leiden mutation
9. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women: Heart and Estrogen/Progestin Replacement Study (HERS) Research Group
10. The HERS trial results: Paradigms lost?
11. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women
12. Hormone replacement therapy and intima-media thickness of the common carotid artery: The Rotterdam study
13. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
14. Associations between carotid atherosclerosis and lipoprotein subclasses: The Healthy Women’s Study
15. Hormone replacement therapy, inflammation, and hemostasis in elderly women
16. Hormone replacement therapy and increased plasma concentration of C-reactive protein
17. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial
18. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
19. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
20. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
21. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) investigators
22. Fibrinogen and risk of cardiovascular disease: The Framingham Study
23. The fibrinolysis and coagulation systems in ischaemic heart disease: Risk markers and their relation to metabolic dysfunction of the arterial intima
24. Relation of serum lipoprotein(a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia
25. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group
26. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: ECAT Study Group European Concerted Action on Thrombosis and Disabilities
27. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
28. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors
29. The effects of transdermal oestradiol and oral progestogens on haemostasis variables
30. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
31. Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transcription and inversion
32. Plasma fibrinogen and factor VII as risk factors for cardiovascular disease
33. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study
34. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature
35. Regulation of fibrinogen assembly: Transfection of HepG2 cells with B beta cDNA specifically enhances synthesis of the three component chains of fibrinogen
36. Fibrinogen genotype and risk of peripheral atherosclerosis
37. Bcl I polymorphism in the fibrinogen beta-chain gene is associated with the risk of familial myocardial infarction by increasing plasma fibrinogen levels: A case-control study in a sample of GISSI-2 patients
38. Beta-fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: The ECTIM Study; Etude Cas-Temoins sur l’Infarctus du Myocarde
39. The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large vessel disease
40. 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: Proposed role for an acute-phase reaction pattern of fibrinogen: REGRESS group
41. Gender-specific associations of the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular disease
42. Polymorphisms of factor V, factor VII, and fibrinogen genes: Relevance to severity of coronary artery disease
43. A common mutation (G455-A) in the b-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease: A study of 9,127 individuals based on the Copenhagen City Heart Study
44. Beta-fibrinogen gene polymorphism (C148 224 T) is associated with carotid atherosclerosis: Results of the Austrian Stroke Prevention Study
45. Human beta-fibrinogen gene expression: Upstream sequences involved in its tissue specific expression and its dexamethasone and interleukin 6 stimulation
46. Linkage disequilibrium across the fibrinogen locus as shown by five genetic polymorphisms, G/A-455 (Hae III), C/T-148 (HindIII/A1uI), T/G+1689 (AvaII), and Bc1I (beta-fibrinogen) and TaqI (alpha-fibrinogen) and their detection by PCR
47. Linkage disequilibrium relationships among four polymorphisms within the human fibrinogen gene cluster
48. Gender-related association between beta-fibrinogen genotype and plasma fibrinogen levels and linkage disequilibrium at the fibrinogen locus in Greenland Inuit
49. Plasma fibrinogen in women: Relationships with oral contraception, the menopause and hormone replacement therapy
50. Haemostatic variables and menopausal status: Influence of hormone replacement therapy
51. Coagulation factor VII and the risk of coronary heart disease in healthy men
52. Fat consumption and factor VII coagulant activity in middle aged men: An association between a dietary and thrombogenic coronary risk factor
53. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease
54. Prospective study of markers of hemostatic function with risk of ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) Study Investigators
55. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study
56. The PLAT Study: Hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: Principal results; PLAT Study Group Progetto Lombardo Atero-Trombosi (PLAT) Study Group
57. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris
58. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men
59. The Arg353Gln polymorphism reduces the level of coagulation factor VII: In vivo and in vitro studies
60. Genetic effects for plasma factor VII levels independent of and in common with triglycerides
61. Two common functional polymorphisms in the promoter region of coagulation factor VII gene determining plasma factor VII activity and mass concentration
62. Factor VII gene polymorphisms contribute about one third of the factor VII level variation in plasma
63. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction
64. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease
65. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and in France but is not a strong indication of MI risk in the ECTIM study
66. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII
67. The effect of hormone replacement therapy on the age-related rise of factor VIIc, and its activity state
68. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives
69. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells
70. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene
71. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes
72. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease
73. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the finnish population
74. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes
75. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease
76. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography
77. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction
78. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men
79. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study: Estude CasTemoins de I’nfarctus du Myocarde
80. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction
81. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: A meta-analysis
82. Effects of hormone replacement therapy on fibrinolysis in postmenopausal women
83. Mechanisms of disease: Plasminogen-activator inhibitor type 1 and coronary artery disease
84. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial
85. Mutation in blood coagulation factor V associated with resistance to activated protein C
86. Activated protein C resistance caused by Arg506Gln mutation in factor Va
87. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis
88. Association of idiopathic thromboembolism with single point mutation at Arg506 of factor V
89. Cardiovascular implications of the factor V leiden mutation
90. Factor V leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
91. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than other countries
92. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease
93. Coagulation factor V (Arg506 224 Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting
94. Resistance to activated protein C in adults with a history of juvenile transient ischemic attacks
95. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects
96. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men
97. Myocardial infarction, Arg 506 Gln factor V mutation, and activated protein C resistance
98. Premature ischaemic heart disease and the gene for coagulation factor V
99. No association of APC resistance with myocardial infarction
100. Resistance to activated protein C and risk of premature myocardial infarction
101. Factor V (Arg506 224 Gln) mutation in young survivors of myocardial infarction
102. Factor V leiden is not a risk factor for arterial vascular disease in the elderly: Results from the Cardiovascular Health Study
103. Heterozygosity for the leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogen
104. Effect of exogenous estrogen on atherothrombotic vascular disease risk related to the presence or absence of the factor V leiden mutation (resistance to activated protein C)
105. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women
106. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men
107. The heterozygous 20210 G/A genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease
108. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease
109. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease
110. A polymorphism of a glycoprotein receptor as an inherited risk factor for coronary thrombosis
111. Platelet glycoprotein IIIa polymorphism in young men with myocardial infarction
112. Association of the platelet Pl(A) polymorphism of glycoprotein IIb/IIIa and the fibrinogen Bbeta 448 polymorphism with myocardial infarction and extent of coronary artery disease
113. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction
114. 2) is an inherited risk factor for premature myocardial infarction in coronary artery disease
115. Polymorphism of the platelet glycoprotein IIIa gene in patients with coronary stenosis
116. 2) is a risk factor for bypass occlusion, myocardial infarction, and death
117. Prothrombotic genetic risk factors in young survivors of myocardial infarction
118. 2 polymorphism of platelet glycoprotein IIIa and the risks of myocardial infarction, stroke, and venous thrombosis
119. Glycoprotein IIIa polymorphism and risk of myocardial infarction
120. Lack of association between platelet glycoprotein IIb/IIIa receptor PlA polymorphism and coronary artery disease or carotid intima-media thickness
121. 2) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM study: Etude Cas-Temoins de l’Infarctus du Myocarde
122. 2 allele and incidence of coronary heart disease: Results from the Atherosclerosis Risk in Communities (ARIC) study
123. 2 polymorphism
124. 2 polymorphism of glycoprotein IIIa and risk of coronary artery disease and restenosis following coronary angioplasty
125. Platelet GP IIIa PlA polymorphisms display different sensitivities to agonists
126. 2 polymorphism
127. 2)
128. Gender differences in platelet GPIIb-IIIa activation
129. Human megakaryocytes and platelets contain the estrogen receptor β and androgen receptor (AR): Testosterone regulates AR expression
130. Integrin polymorphisms as risk factors for thrombosis
131. Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction
132. PlA polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement
133. The PlA polymorphism of glycoprotein IIIa functions as a modifier for the effect of estrogen on platelet aggregation
134. 2 and ACE D allele polymorphisms are synergistic for the risk of recurrent events in patients post myocardial infarction and pravastatin reduces this risk
135. Prothrombin G20210A polymorphism and thrombophilia